Shattuck Labs provided a corporate update, emphasizing considerable progress in the development of SL-325, its potential first-in-class DR3 blocking antibody. The company remains optimistic about SL-325's ability to achieve a complete blockade of the DR3/TL1A signaling pathway based on preclinical non-human primate (NHP) studies.
Key milestones for 2025 include an Investigational New Drug (IND) filing for SL-325 expected in the third quarter. The Phase 1 clinical trial for SL-325 is anticipated to commence later in the year, marking a critical step towards human clinical evaluation.
As of September 30, 2024, Shattuck Labs reported approximately $90.1 million in cash and cash equivalents and investments. This financial position is projected to fund planned operations into 2027, supporting the advancement of SL-325 through its initial clinical development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.